Zero people have such tales about Robert Leverte, which is why news of his pending induction into the Medical Advertising Hall of Fame was received warmly when it was made public last October.
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled
Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Four data aces share their backgrounds, inspirations, and guiding philosophies
Read the January 2018 issue in its entirety.
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
Not only isn't print dead, as ahead-of-themselves media wonks have claimed for the past decade, but it's thriving in a most unlikely environment: the point of care
For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market
Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?
The group's reports, received with great interest by insurers and the Department of Veteran Affairs, have concluded certain high-profile drugs aren't worth the cost. Pharma still hasn't decided whether ICER is friend or foe.
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
Innovation-minded executives share their thoughts and predictions for the year ahead.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
Read the December 2017 issue in its entirety.
Read the November 2017 issue in its entirety.
To remain relevant, speakers bureaus must evolve to a strategic marketing tactic with personalized messaging to the customer.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
This year's offering includes access to the most current and in-depth data on salary and compensation trends, job satisfaction, recruitment and retention tactics, and more.
Read the October 2017 issue in its entirety, including our Career and Salary Survey.
The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
The successes of these pharma execs show that there's no one path to professional bliss.
Now that Facebook, Apple, and Google have set their sights on healthcare, agencies find themselves under pressure from yet another flank.
Salaries are up — by a lot — and marketers are enthusiastic about their career prospects.
Read the September 2017 issue in its entirety, including how marketing can save clinical trials.
The answer: it depends on what phase the trial is in.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
The best marketers possess a mix of scientific know-how, digital dexterity, and unflappability. To keep them, agencies need to revise their thinking and tactics.
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.
Read the August 2017 issue in its entirety, including our recap of the MM&M Hall of Femme event.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
Read the 2017 Agency Issue in its entirety.
Meet 13 of our 16 Hall of Femme honorees.
Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.
McCann Health, Cannes Lions Healthcare Network of the Year, hosted a roundtable to discuss the role of creativity in a new world order where populism is undermining trust.
Here are nine agencies that are gaining traction in healthcare marketing.
Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.
Here you'll find the last four years of the MM&M Agency Issue.
Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.
Havas Health & You, WPP Health & Wellness, and Klick Health reported the highest revenue last year.
The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.
Read on for more about the top performing firms, the trends shaping the business, and the story behind each of the top 100 agencies.
Here you'll find everything from the Patient Journey 2017 supplement to our June issue.
Here you'll find everything from our June 2017 issue, including our Pharma Report, our Hall of Femme, and two roundtable discussions on media and oncology.
In apportioning their media budgets, pharma companies continue to straddle the line between new and traditional strategies.
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.
Here you'll find everything from our May 2017 issue, including our Top 40 Transformers, deep dive into autoimmune drugs, and more.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Here you'll find Sara Holoubek's deep dive into how pharma is tackling some of its biggest challenges.
Under Duato, the leadership team for Johnson & Johnson's pharma group includes six women. "We don't just talk about it," he says.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.
A WebMD survey finds that patients are more engaged when they share their own health with their doctors.
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Drugmakers again spent more on DTC advertising in 2016 than the year before.
Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.
Seven execs from A-list agencies weigh in on talent acquisition and retention.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.
He describes his current charge as "transforming a more creative occupation into a science."
Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."